Steven Gutman, director of the Office of In Vitro Diagnostic Device Safety and Evaluation, will leave the US Food and Drug Administration by the end of the year for a post in academia, ProteoMonitor’s sister publication Pharmacogenomics Reporter reported this week.
“I made the very difficult decision that it was time for a change,” Gutman told PGx Reporter.
Gutman said he plans to join the University of Central Florida in January, where he will be a professor of pathology and part of the founding faculty at the university’s new medical school.
“I will miss the people, the mission, and the fire of OIVD,” Gutman said. “It has been a lovely ride. I do hope to remain involved in personalized health care, both scientific and policy.”
The FDA has not yet announced who will replace Gutman.
In addition to his teaching post at UCF, Gutman said he also hopes to spend time writing and consulting.
Gutman, who has been at the agency for nearly 17 years, has been the top man at OIVD since November 2002, when the division was formed to consolidate all regulatory activities for in vitro diagnostics.
Quanterix said this week that Robert Corn has joined its scientific advisory board.
Corn is a professor of chemistry and of biomedical engineering at the University of California, Irvine. His main area of research includes development of new methods for detecting binding of biomolecules to surfaces and chemical modification strategies to control specific and non-specific adsorption of biopolymers to a variety of surfaces.